Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 5,310 matching trials from the live ClinicalTrials.gov search.

Filters: Louisville, Kentucky Clear all

Conditions: Schizophrenia, Autism-Related Irritability
Interventions: KarXT, KarX-EC; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 58
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 48 more

Conditions: Atrophy, Geographic
Interventions: GSK933776, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 55 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 40
States / cities: Phoenix, Arizona • Arcadia, California • Irvine, California + 34 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Iscar Quercus, Gemcitabine; Drug
Lead sponsor: Kentuckiana Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Epilepsy
Interventions: RNS System; Device
Lead sponsor: NeuroPace; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 35
States / cities: Birmingham, Alabama • Irvine, California • Los Angeles, California + 27 more

Conditions: Obesity, Overweight
Interventions: Retatrutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 15 more

Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Synchronous Bilateral Breast Carcinoma
Interventions: Health Education Program, Weight Loss Intervention; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1464
States / cities: Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more

Conditions: Multiple Myeloma
Interventions: Selinexor, Dexamethasone; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more

Conditions: Burns
Interventions: Enzymatic agent, Bacitracin; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Melanoma Stage III, Melanoma Stage IV
Interventions: Beta-Glucan; Dietary Supplement
Lead sponsor: Kelly McMasters; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: SAR156597, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 18
States / cities: Phoenix, Arizona • Jacksonville, Florida • Loxahatchee Groves, Florida + 15 more

Conditions: Hypertriglyceridemia
Interventions: ARI-3037MO, Placebo; Drug
Lead sponsor: Arisaph Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Tustin, California • Louisville, Kentucky • Auburn, Maine + 2 more

Conditions: Type 1 Diabetes
Interventions: Resistance Training; Other
Lead sponsor: University of Louisville; Other
Eligibility: 13 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more

Conditions: Malignant Melanoma
Interventions: Placebo, Vemurafenib, Cobimetinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more

Conditions: Atopic Dermatitis, Eczema, Atopic
Interventions: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle; Drug
Lead sponsor: Ralexar Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more

Conditions: Open Angle Glaucoma
Interventions: Streamline Surgical System, iStent Inject W; Device
Lead sponsor: New World Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 18
States / cities: Fayetteville, Arkansas • Newport Beach, California • Torrance, California + 15 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 51
States / cities: Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more

Conditions: Prostate Cancer
Interventions: brachytherapy, iodine I 125, radiation therapy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 236
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more

Conditions: Lung Cancer
Interventions: monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, radiation therapy; Biological · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 218
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more

Conditions: Atopic Dermatitis
Interventions: EDP1815; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 19 more

Conditions: Carcinoma, Small Cell Lung
Interventions: RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide; Combination Product · Drug
Lead sponsor: EpicentRx, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 18
States / cities: Denver, Colorado • Orange City, Florida • Orlando, Florida + 15 more

Conditions: Healthy Subjects
Interventions: 13 valent pneumococcal conjugate vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 15 Months to 18 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 36
States / cities: Benton, Arkansas • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab, Questionnaire Administration, Venetoclax; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 625
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 443 more

Search by objective public record fields.

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

RNS® System Epilepsy Post-Approval Study

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Breast Cancer WEight Loss Study (BWEL Study)

Selinexor Treatment of Refractory Myeloma

Comparison of Wound Bed Establishment in Facial Burns

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

Resistance Training in Type 1 Diabetes Mellitus

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

A Study in Subjects With Moderate Atopic Dermatitis

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer

Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery

A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials

RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study